AVENUE THERAPEUTICS

Avenue Therapeutics is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases. The Company is advancing a diverse portfolio that includes first-in-class and best-in-class programs in a high-value neurologic landscape with significant unmet patient need... Avenue is focused on delivering impactful therapies to patients suffering from neurologic diseases. We believe our unique pipeline of innovative treatments has the potential to overcome limitations of existing treatment options and ultimately transform patient outcomes... Avenue Therapeutics, Inc. (Nasdaq: ATXI) is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases. The Company is currently developing three assets including AJ201, a first-in-class asset for spinal and bulbar muscular atrophy, BAER-101, an oral small molecule selective GABA-A α2/3 receptor positive..

Also known as: Avenue, Avenue Therapeutics, Inc.

Primary location: Bay Harbor Islands United States